Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Peak Retirement Planning Inc. Buys New Position in Exelixis, Inc. $EXEL
03:12am, Tuesday, 03'rd Feb 2026
Peak Retirement Planning Inc. bought a new stake in shares of Exelixis, Inc. (NASDAQ: EXEL) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. T
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted
Strs Ohio Has $260,000 Position in Exelixis, Inc. $EXEL
04:32am, Monday, 02'nd Feb 2026
Strs Ohio trimmed its position in Exelixis, Inc. (NASDAQ: EXEL) by 86.8% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 6,301 shares of the biotechnolog
2 Stocks That Could Soar This Year
06:53pm, Saturday, 31'st Jan 2026
Exelixis and Summit Therapeutics could have significant catalysts this year. Both have drug candidates that could drive strong financial results for a while.
Exelixis, Inc. $EXEL Shares Sold by Nan Fung Trinity HK Ltd.
03:23am, Saturday, 31'st Jan 2026
Nan Fung Trinity HK Ltd. lowered its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 46.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
Exelixis, Inc. $EXEL Shares Purchased by Lingohr Asset Management GmbH
03:23am, Saturday, 31'st Jan 2026
Lingohr Asset Management GmbH raised its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 1,258.9% during the third quarter, according to the company in its most recent filing with the Securities and Exch
Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval
10:06pm, Wednesday, 28'th Jan 2026
Exelixis offers strong growth potential, trading at 14x 2026E EPS, below sector median, with robust oncology franchises and disciplined R&D spending. Cabozantinib remains the near-term growth driver,
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
04:05pm, Tuesday, 27'th Jan 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the
EXEL vs. EXAS: Which Stock Is the Better Value Option?
12:40pm, Tuesday, 27'th Jan 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Exact Sciences (EXAS). But which of these two stocks offers value investor
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 27'th Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis: High-Growth Oncology Name Trading At A Discount
07:22am, Thursday, 22'nd Jan 2026
Exelixis offers exceptional medium-term growth, driven by Cabometyx's market leadership and a robust pipeline, yet remains undervalued versus peers. EXEL maintains high profitability and growth withou
SG Americas Securities LLC Lowers Holdings in Exelixis, Inc. $EXEL
06:22am, Tuesday, 20'th Jan 2026
SG Americas Securities LLC lowered its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 69.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 15'th Jan 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Wednesday, 14'th Jan 2026
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CoreCap Advisors LLC Has $137,000 Stock Holdings in Exelixis, Inc. $EXEL
04:47am, Wednesday, 14'th Jan 2026
CoreCap Advisors LLC reduced its stake in Exelixis, Inc. (NASDAQ: EXEL) by 77.9% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange C
